Process

Our Model

Origin actively manages its portfolio company investments and provides investors with exposure to early-stage investment opportunities.

Deal Flow

Our investment mandate is simple: we focus on companies with an exemplary management team and high growth potential.
Estimated number of global psychedelic companies by 2022

300+

Origin performs high-level review

150

Initial due diligence including early discussions with management

60

Investment committee review

30

Management and operational due diligence

15

Negotiation

8

Investment Strategy

Our experienced leadership team has decades of collective experience and has access to a diverse deal pipeline. Our due diligence process has be implemented to optimize the deal pipeline and select high potential opportunities.

We also support the companies we invest in by serving on their advisory boards and board of directors.

Join Our Portfolio

Companies interested in partnering with Origin Therapeutics can submit a short summary of the opportunity using the form below.